Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO)

• Qualitative and quantitative toxicities [ Time Frame: 6 months ]
• Quality of life [ Time Frame: 6 months ]
• Overall survival [ Time Frame: 5 years ]

• Overall survival
• Qualitative and quantitative toxicities
• Quality of life

This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin in patients with epithelial ovarian cancer in late relapse (> 6 months).

The main purpose of this research study is to find out if treatment of late relapse of ovarian or fallopian tube or primary peritoneal cancer with liposomal doxorubicin (Caelyx) combined with carboplatin will control the tumor growth at least as well as standard treatment of paclitaxel and carboplatin. And it is hoped that substituting paclitaxel with Caelyx in combination with carboplatin will improve the tolerance of the treatment program with at least the same efficacy and fewer side effects.

• Ovarian Cancer
• Fallopian Tube Cancer

• Drug: Pegylated liposomal doxorubicin
  30 mg/m² every 4 weeks during 6 cycles or until progression
  Other Name: Caelyx
• Drug: Carboplatin
  AUC 5 every 3/4 weeks during 6 cycles or until progression
  Other Name: generic drug
• Drug: Paclitaxel
  175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
  Other Name: generic drug

• Active Comparator: Standard
  Paclitaxel-Carboplatin
  Interventions:

  • Drug: Carboplatin
  • Drug: Paclitaxel
• Experimental: Experimental
  Caelyx-Carboplatin
  Interventions:

  • Drug: Pegylated liposomal doxorubicin
  • Drug: Carboplatin

Inclusion Criteria:

• Patients aged > 18
• Histologically proven diagnosis of cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors
• Measurable disease (Response Evaluation Criteria in Solid Tumor [RECIST] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG] criteria) or with histologically proven diagnosis of relapse
• Disease in progression > 6 months after a first or second platinum-based line. Patients should have previously received a taxane derivative.
• ECOG performance status < 2
• Life expectancy of at least 12 weeks
• Adequate bone marrow, renal, and hepatic function

Exclusion Criteria:

• Ovarian tumors of low malignant potential
• Non-epithelial ovarian or mixed epithelial/non-epithelial tumors
• Previous radiotherapy
• Prior diagnosis of malignancy
• Bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases
• Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 1
• History of congestive heart failure (New York Heart Association [NYHA] classification > 2), history of myocardial infarction within the last 6 months, or history of atrial or ventricular arrhythmias
• Severe active infection
• Severe hypersensitivity to products containing Cremophor EL and/or to compounds chemically related to paclitaxel, carboplatin or Caelyx
• Fertile women not using adequate contraceptive methods
• Pregnant or breast feeding women

• Schering-Plough
• Arbeitsgemeinschaft Gynaekologische Onkologie Austria
• AGO Study Group
• ANZGOG
• European Organisation for Research and Treatment of Cancer - EORTC
• NCIC CTG
• NSGO